- Home
- BLW vs TERN Comparison
BLW vs TERN Comparison
Compare BLW & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLW
- TERN
- Stock Information
- Founded
- BLW 2003
- TERN 2017
- Country
- BLW United States
- TERN United States
- Employees
- BLW N/A
- TERN N/A
- Industry
- BLW Other Consumer Services
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- BLW Consumer Discretionary
- TERN Health Care
- Exchange
- BLW Nasdaq
- TERN Nasdaq
- Market Cap
- BLW 548.9M
- TERN 495.2M
- IPO Year
- BLW N/A
- TERN 2021
- Fundamental
- Price
- BLW $14.06
- TERN $7.05
- Analyst Decision
- BLW
- TERN Buy
- Analyst Count
- BLW 0
- TERN 5
- Target Price
- BLW N/A
- TERN $15.63
- AVG Volume (30 Days)
- BLW 85.9K
- TERN 1.1M
- Earning Date
- BLW 01-01-0001
- TERN 08-05-2025
- Dividend Yield
- BLW 8.83%
- TERN N/A
- EPS Growth
- BLW N/A
- TERN N/A
- EPS
- BLW 1.81
- TERN N/A
- Revenue
- BLW N/A
- TERN N/A
- Revenue This Year
- BLW N/A
- TERN N/A
- Revenue Next Year
- BLW N/A
- TERN N/A
- P/E Ratio
- BLW $7.73
- TERN N/A
- Revenue Growth
- BLW N/A
- TERN N/A
- 52 Week Low
- BLW $12.35
- TERN $1.87
- 52 Week High
- BLW $14.26
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- BLW 41.82
- TERN 73.83
- Support Level
- BLW $14.11
- TERN $6.43
- Resistance Level
- BLW $14.21
- TERN $6.34
- Average True Range (ATR)
- BLW 0.08
- TERN 0.44
- MACD
- BLW -0.01
- TERN 0.05
- Stochastic Oscillator
- BLW 4.55
- TERN 96.07
About BLW Blackrock Limited Duration Income Trust
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.